Get the Stockscreener App
15.87
31.15%
-7.18
After Hours:
16.00
0.13
+0.82%
Dyne Therapeutics Inc stock is traded at $15.87, with a volume of 9.78M.
It is down -31.15% in the last 24 hours and down -43.98% over the past month.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
See More
Previous Close:
$23.05
Open:
$20
24h Volume:
9.78M
Relative Volume:
9.39
Market Cap:
$1.62B
Revenue:
-
Net Income/Loss:
$-257.60M
P/E Ratio:
-4.4206
EPS:
-3.59
Net Cash Flow:
$-220.31M
1W Performance:
-35.90%
1M Performance:
-43.98%
6M Performance:
-59.87%
1Y Performance:
-8.48%
1-Day Range:
$14.79
$20.00
1-Week Range:
$14.79
$24.98
52-Week Range:
$14.79
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
15.87 | 1.62B | 0 | -257.60M | -220.31M | -3.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.56 | 105.47B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.88 | 76.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
656.26 | 39.24B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.98 | 30.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.85 | 29.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week LowHere's What Happened - MarketBeat
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potenti - Investing.com South Africa
Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? - Benzinga
Dyne Therapeutics stock tumbles following trial data By Investing.com - Investing.com Nigeria
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownHere's Why - MarketBeat
Dyne Therapeutics stock tumbles following trial data - Investing.com
Why Dyne Therapeutics Shares Are Shifting - TipRanks
Dyne Therapeutics Advances Clinical Trials for DM1 and DMD - TipRanks
Dyne Therapeutics Reports New Clinical Data Showing - GlobeNewswire
Dyne Therapeutics' DM1 Treatment Shows Breakthrough Results, Plans Accelerated FDA Filing - StockTitan
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Dyne Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dyne Therapeutics shares jump ahead of clinical data review By Investing.com - Investing.com Canada
Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire
Dyne Therapeutics Sets Key Date for ACHIEVE Trial Data Release in Early 2025 - StockTitan
Principal Financial Group Inc. Reduces Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
(DYN) Proactive Strategies - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.7%Here's What Happened - MarketBeat
Dyne Therapeutics initiated with Outperform at Baird - MSN
Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4%What's Next? - MarketBeat
Oppenheimer reiterates Outperform rating on Dyne Therapeutics stock ahead of readout - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by Analysts - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Where are the Opportunities in (DYN) - Stock Traders Daily
Geode Capital Management LLC Acquires 84,760 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Barclays PLC Purchases 128,246 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Wellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Franklin Resources Inc. Cuts Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up – Still a Buy? - Defense World
State Street Corp Raises Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Gap UpWhat's Next? - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Upgraded at Raymond James - MarketBeat
How to Take Advantage of moves in (DYN) - Stock Traders Daily
Baird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. Baird - MarketBeat
29,694 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Y Intercept Hong Kong Ltd - MarketBeat
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Baird sets $46 target on Dyne Therapeutics, sees upside By Investing.com - Investing.com UK
Dyne therapeutics SVP Richard Scalzo sells $40,914 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $40,914 in stock - Investing.com India
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 6,784 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne therapeutics' chief scientific officer sells $65,632 in stock By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - The Eastern Progress Online
Point72 Asset Management L.P. Sells 255,038 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
The Manufacturers Life Insurance Company Sells 20,029 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
The Manufacturers Life Insurance Company Has $3.82 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Dec 11 '24 |
Sale |
28.12 |
1,455 |
40,915 |
127,078 |
3.54%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):